Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes.

Geanes AR, Cho HP, Nance KD, McGowan KM, Conn PJ, Jones CK, Meiler J, Lindsley CW
Bioorg Med Chem Lett. 2016 26 (18): 4487-4491

PMID: 27503678 · PMCID: PMC4996684 · DOI:10.1016/j.bmcl.2016.07.071

This Letter describes a ligand-based virtual screening campaign utilizing SAR data around the M5 NAMs, ML375 and VU6000181. Both QSAR and shape scores were employed to virtually screen a 98,000-member compound library. Neither approach alone proved productive, but a consensus score of the two models identified a novel scaffold which proved to be a modestly selective, but weak inhibitor (VU0549108) of the M5 mAChR (M5 IC50=6.2μM, M1-4 IC50s>10μM) based on an unusual 8-((1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl)-1-oxa-4-thia-8-azaspiro[4,5]decane scaffold. [(3)H]-NMS binding studies showed that VU0549108 interacts with the orthosteric site (Ki of 2.7μM), but it is not clear if this is negative cooperativity or orthosteric binding. Interestingly, analogs synthesized around VU0549108 proved weak, and SAR was very steep. However, this campaign validated the approach and warranted further expansion to identify additional novel chemotypes.

Copyright © 2016 Elsevier Ltd. All rights reserved.

MeSH Terms (9)

Animals CHO Cells Cricetulus Drug Discovery Humans Ligands Muscarinic Antagonists Quantitative Structure-Activity Relationship Receptor, Muscarinic M5

Connections (4)

This publication is referenced by other Labnodes entities: